Sanofi: Triggering Regenerative Functions

February 2010. What requirements stem cell technologies have to fulfil? What is the relationship to biomarker development? Which types of stem cells are most promising in order to meet Sanofi-Aventis’ strategic development goals? What combination with small molecules? Which complementary technologies are needed? Kurt Stoeckli, at the time Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville (FR).

Includes Sanofi Aventis’ early - / late-stage pipelines Pharma & Vaccines 2010Reading time: 9 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section